Adaptimmune Therapeutics
ADAP
$1.19
Share price
-1.65%
Change (1 day)
-13.14%
Change (1 year)
Categories
Adaptimmune Therapeutics (ADAP) - Cash on Hand
Cash on Hand as of December 2023 : $0.14 B
According to Adaptimmune Therapeutics's latest financial reports the company has $0.14 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Adaptimmune Therapeutics - Cash on Hand chart (from 2014 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $0.14 B | -28.18% |
| 2022-12-31 | $0.20 B | -44.64% |
| 2021-12-31 | $0.36 B | 0.37% |
| 2020-12-31 | $0.36 B | 311.22% |
| 2019-12-31 | $89.54 M | -56.35% |
| 2018-12-31 | $0.20 B | -1.5% |
| 2017-12-31 | $0.20 B | 14.76% |
| 2016-12-31 | $0.18 B | |
| 2015-06-30 | $0.28 B | 454.55% |
| 2014-06-30 | $51.27 M | 20592.35% |
| 2013-06-30 | $0.24 M | -91.8% |
| 2012-06-30 | $3.02 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 uniQure QURE | $0.61 B | 320.51% | 🇳🇱 Netherlands |
 Novavax NVAX | $0.56 B | 286.90% | 🇺🇸 USA |
 Exelixis EXEL | $0.99 B | 577.36% | 🇺🇸 USA |
 Enzo Biochem ENZ | $60.24 M | -59.00% | 🇺🇸 USA |